Portfolio of Innovative Drugs
Milestones
Portfolio of Innovative Drugs
MILESTONES
2013+
- June 2013 - Spun-off from Cedars-Sinai Medical Center
- June 2014 - Raised $525k from Founders / Pennsylvania Biotechnology Grant
- July 2016 - Name changed to Kairos Pharma and licensed immunotherapy technology from Cedars-Sinai Medical Center
- November 2019 - Merged with AcTcell Biopharma
- July 2021 - Merged with Enviro Therapeutics
2022
- Preclinical work for ENV105 Prostate Cancer Phase II, ENV105 Non-Small Cell Lung Cancer Phase I, KROS-201 Glioblastoma Phase I
- IND for KROS 201 cleared for recurrent glioblastoma
2023
- KROS-101 GITR agonist molecule and KROS-102 antagonist GITR molecule Preclinical studies
- IND approved for Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV 105
2024
- Phase I and II multi-center trials with ENV 105 enrolling
- Preclinical development of KROS 101, 102, 301, 401
- Safety data from Phase II trial and Phase I trial
2025
- Efficacy data from Phase II trial and Phase I trial
- 5-year Horizon for ENV105 FDA Approval with a Maturing Pipeline of Broader Prospective Applications
- Phase I trials for KROS 101